The project, funded through the European Commission’s 6th Framework Programme, sets the stage for an open-access resource of binding molecules directed against the entire human proteome, the full set of over 100,000 proteins specified by the human genome.
Established with initial funding of €1.8 M over 4 years, ‘ProteomeBinders’ is co-ordinated by Dr Mike Taussig, Head of the Technology Research Group at the Babraham Institute, and brings together 26 European partners from 12 countries, and two from the USA.
A major challenge of the post-genomic era is to understand how the information encoded within the genome, and expressed as the proteome, choreographs the biological organisation of cells, tissues and organisms. “This requires a comprehensive, standardised collection of specific protein-binding molecules. ‘ProteomeBinders’ aims to provide the tools required to detect and characterise all the relevant human proteins in tissues and fluids in health and disease,” commented Mike Taussig. Currently, antibodies are the most widely used protein-binders, but novel binder types based on alternative protein scaffolds, nucleic acids, peptides and chemical entities each have significant advantages and will be evaluated through this collaboration.
Currently there is no pan-European platform for the systematic development and quality control for these essential reagents. The ‘ProteomeBinders’ consortium will coordinate a new European resource, by integrating existing infrastructures, reviewing technologies and high-throughput production methods, standardising tools and applications, and establishing a database.
As one of the largest genome-scale projects in Europe, aiming ultimately to produce and collect hundreds of thousands of specific binders, this resource brings benefits to basic and applied research. The resource will impact on healthcare, diagnostics, target discovery for drug intervention and therapeutics, and will consequently deliver advantages to the research, medical and biotechnology communities.Contact details:
Cohesin down-regulation drives hematopoietic stem cell aging
14.12.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
Magic number colloidal clusters
13.12.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Ecology, The Environment and Conservation
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy